Early risk assessment of metabolic bone diseases and accompanying therapeutic diagnostics

Since its spin-off from the GEOMAR Helmholtz Centre in 2018, osteolabs has launched the OsteoTest product family for the early determination of individual bone calcium loss. Numerous patients have thus been able to determine their personal risk for possible clinical pictures such as osteoporosis and fatigue fractures.

The CIM biomarker can be used to detect the first signs of bone calcium loss, well before the standard X-ray imaging procedure (DXA). The disadvantage of the DXA procedure is that a diagnosis can only be made when bone substance has already been noticeably degraded. What may remain undetected on the X-ray image for years is revealed earlier by the OsteoTest. It provides certainty and the chance to start treatment early before the bone is damaged by excessive calcium loss and becomes porous.

With the OsteoTest procedure, doctors can obtain early indications of possible clinical pictures such as osteoporosis and fatigue fractures in competitive sport and thus prescribe individualised therapy for their patients.
In addition to the disease area of osteoporosis, research projects are currently underway on chronic kidney dysfunction with a particular focus on renal osteodystrophy and bone metastasising prostate cancer.